E. Huff
NaturalNews.com
December 18, 2009

A federal lawsuit has been filed against pharmaceutical giant AstraZeneca for its role in paying Chicago psychiatrist Dr. Michael Reinstein nearly $500,000 over the course of a decade to conduct research and to promote its anti-psychotic drug, Seroquel. Reinstein is being accused of wrongfully preying on thousands of mentally-ill patients in order to rake in profits for AstraZeneca.

Reinstein has a long history of working with AstraZeneca, receiving regular payments for speeches he would make across the country promoting the drug. AstraZeneca was also paying a for-profit research company, Uptown Research Institute, who in turn was paying Reinstein consulting fees for his services.

Cited in the lawsuit was the fact that Reinstein would continually prescribe roughly double the amount of drugs other psychiatrists would prescribe for the same conditions. When patients would report their pain and suffering due to the tremendous side effects of such drugs and their abnormally high dosages, Reinstein would largely ignore their concerns.

Read entire article: http://www.naturalnews.com/027765_psychiatrists_Seroquel.html

« Return to news items

News Feed

Related Posts

• Drugmaker pays psychiatrist nearly $500,000 to promote antipsychotic drug Seroquel despite misgivings about his research (0)
• Tighter rules sought against using anti-psychotic drugs to chemically restrain the frail & elderly (1)
• Drugged to Death: Soldiers returning from war are being given deadly cocktails of psychiatric drugs (0)
• Drugging Kids For Profit: Powerful & dangerous antipsychotic drugs being used on kids more and more often (0)
• US Kids Represent Psychiatric Drug Goldmine (0)

Tags: anti-psychotic, antipsychotic, AstraZeneca, Dr. Michael Reinstein, psychiatrist, Seroquel, Uptown Research Institute

This entry was posted on Sunday, December 20th, 2009 at 3:45 pm and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed.

You can leave a response, or trackback from your own site.